ACTELION LTD Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 7 of 7 Posts
Johnson & Johnson Acquires European Biotech Giant Actelion For $30 Billion
Article By: Tyler Durden Thursday, January 26, 2017 6:17 AM EDT
J&J initially abandoned talks over price, only to resume them about a week later after the companies entered into exclusive negotiations. The deal is expected to close by Q2. Shares in Swiss company Actelion surged 21% following the announcement.
In this article: JNJ, ALIOF
Read
Conatus Soars On Novartis Deal, Early FDA Nod For Clovis Drug
Article By: Arpita Dutt Wednesday, December 21, 2016 10:55 AM EDT
Conatus is ending the year on a high note with the company signing a lucrative deal with Swiss pharma giant, Novartis. Investors applauded the deal sending the company’s shares soaring 141.3%.
In this article: ALIOF, ALXN, BIIB, CLVS, GILD, CNAT, TSRO
Read
Actelion Remains In M&A Spotlight, ASH Data In Focus
Article By: Arpita Dutt Wednesday, December 7, 2016 6:01 PM EDT
Switzerland-based Actelion continued to be a part of acquisition chatter with Sanofi now rumored to be interested in the company.
In this article: ALIOF, AMGN, CELG, VRTX, ABBV, AGIO, KITE
Read
Lilly Alzheimer's Drug Fails, J&J In Acquisition Talks With ALIOF
Article By: Arpita Dutt Monday, November 28, 2016 11:59 AM EDT
Does Johnson & Johnson’s interest in acquiring Actelion imply the beginning of increased merger and acquisition (M&A) activity in the pharma and biotech sector?
In this article: AGN, AZN, BMY, JNJ, LLY, MRK, ALIOF
Read
Lung Disease Stocks Advance After Actelion Approached By J&J
Article By: The Fly Friday, November 25, 2016 5:04 PM EDT
Actelion, a Switzerland-based biopharmaceutical company, and drug giant Johnson & Johnson confirmed they were in preliminary discussions regarding a potential transaction.
In this article: ALIOF, JNJ Also: SNY, NVS, AHPI, INSM, PRQR, UTHR
Read
Four Best Biotech Stocks Of The First Quarter Of 2016
Article By: Zacks Investment Research Sunday, April 3, 2016 7:19 AM EDT
The entry of the first FDA-approved biosimilar, Zarxio, a biosimilar version of Amgen’s blockbuster drug, Neupogent, last year has left biotech companies vying to enter this high revenue generating space. Biosimilars are the next big thing.
In this article: KIN, CRMD, ALIOF, MESO Also: AMGN, GILD, SHPG, BXLT
Read
5 Biotech Stocks With Good Growth Prospects
Article By: Zacks Investment Research Tuesday, November 10, 2015 5:21 PM EDT
Massive swings experienced by the biotech sector since September has proved once again that these stocks aren’t for the faint-hearted investor.
In this article: ENZ, ALIOF, EXEL, GILD, RTRX Also: UNH, DYAX, AMGN, SHPG
Read
1 to 7 of 7 Posts